Oncotelic Therapeutics Stock Current Liabilities
| OTLCDelisted Stock | USD 0.02 0 6.38% |
Oncotelic Therapeutics fundamentals help investors to digest information that contributes to Oncotelic Therapeutics' financial success or failures. It also enables traders to predict the movement of Oncotelic OTC Stock. The fundamental analysis module provides a way to measure Oncotelic Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Oncotelic Therapeutics otc stock.
Oncotelic |
Oncotelic Therapeutics OTC Stock Current Liabilities Analysis
Oncotelic Therapeutics' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
CompetitionIn accordance with the recently published financial statements, Oncotelic Therapeutics has a Current Liabilities of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
Oncotelic Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oncotelic Therapeutics' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Oncotelic Therapeutics could also be used in its relative valuation, which is a method of valuing Oncotelic Therapeutics by comparing valuation metrics of similar companies.Oncotelic Therapeutics is currently under evaluation in current liabilities category among its peers.
Oncotelic Fundamentals
| Return On Equity | 0.5 | ||||
| Return On Asset | -0.13 | ||||
| Current Valuation | 31.34 M | ||||
| Shares Outstanding | 391.11 M | ||||
| Shares Owned By Insiders | 55.93 % | ||||
| Number Of Shares Shorted | 662.75 K | ||||
| Price To Earning | 2.16 X | ||||
| Price To Book | 0.89 X | ||||
| Price To Sales | 8.40 X | ||||
| Gross Profit | 1.74 M | ||||
| EBITDA | (8.45 M) | ||||
| Net Income | (9.39 M) | ||||
| Cash And Equivalents | 399.77 K | ||||
| Total Debt | 9.8 M | ||||
| Debt To Equity | 0.40 % | ||||
| Current Ratio | 0.03 X | ||||
| Book Value Per Share | 0.06 X | ||||
| Cash Flow From Operations | (4.43 M) | ||||
| Short Ratio | 8.04 X | ||||
| Earnings Per Share | 0.02 X | ||||
| Target Price | 4.0 | ||||
| Number Of Employees | 16 | ||||
| Beta | 0.19 | ||||
| Market Capitalization | 23.9 M | ||||
| Total Asset | 23.61 M | ||||
| Z Score | 1.2 | ||||
| Net Asset | 23.61 M |
About Oncotelic Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oncotelic Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oncotelic Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oncotelic Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Oncotelic OTC Stock
If you are still planning to invest in Oncotelic Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oncotelic Therapeutics' history and understand the potential risks before investing.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |